Respiratory infection in the chronically critically ill patient. Ventilator-associated pneumonia and

Q A Ahmed1, M S Niederman

  • 1Department of Critical Care Medicine, King Fahad National Guard Hospital, Riyadh, Kingdom of Saudi Arabia.

Insights

Long-term ventilated patients face high risks of hospital-acquired pneumonia and tracheobronchitis, especially within the first week. Prompt, appropriate treatment, potentially including aerosol therapy for resistant infections, is crucial.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pulmonary Medicine

Background:

  • Long-term mechanical ventilation is associated with a significant risk of nosocomial pneumonia and tracheobronchitis.
  • Infection risk increases with ventilation duration, peaking in the first week post-intubation.
  • A 'survivor effect' may explain lower daily risk in long-term ventilated patients compared to acutely ill patients.

Purpose of the Study:

  • To review risk factors, pathogens, and treatment strategies for nosocomial infections in long-term ventilated patients.
  • To highlight the importance of airway colonization and host defense in infection development.
  • To discuss the role of adjunctive therapies in managing resistant infections.

Main Methods:

  • Review of existing literature on nosocomial infections in mechanically ventilated patients.
  • Analysis of factors predisposing to infection, including host defenses and bacterial exposure.
  • Discussion of common pathogens and therapeutic approaches.

Main Results:

  • Infections are often preceded by airway colonization with gram-negative enteric bacteria.
  • Long-term ventilated patients frequently develop infections with highly resistant organisms.
  • Systemic antibiotics are not always effective; adjunctive aerosol therapy may benefit some patients.

Conclusions:

  • Prompt and appropriate therapy is essential for treating infections in long-term ventilated patients.
  • Adjunctive aerosol therapy may be beneficial, particularly for infections caused by highly resistant pathogens.
  • Minimizing bacterial exposure through proper respiratory device care is critical.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...